A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

Launched by VERTEX PHARMACEUTICALS INCORPORATED · Apr 5, 2022

Keywords

ClinConnect Summary

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Female participants must be of non-childbearing potential
• • Body mass index (BMI) of 18.0 to 32.0 kilograms per meter square (kg/m\^2)
• • A total body weight greater than (\>) 50 kg
• Key Exclusion Criteria:
• • History of febrile illness or other acute illness within 14 days before the first dose of study drug
• • Any condition possibly affecting drug absorption
• • Other protocol defined Inclusion/Exclusion criteria may apply.